| Literature DB >> 29080081 |
Gaëlle Collet1, Nathalie Parodi1, Kevin Cassinari1, Zoe Neviere1,2, Fanny Cohen2, Céline Gasnier2, Afane Brahimi1, François Lecoquierre1, Jean-Christophe Thery1,3, Isabelle Tennevet1,3, Elodie Lacaze4, Pascaline Berthet2, Thierry Frebourg5,6.
Abstract
One of the main challenges in cancer genetics is responding to the exponential demand for genetic counseling, especially in patients with breast and/or ovarian cancer. To address this demand, we have set up a new procedure, based on pre-genetic counseling telephone interviews (PTI) followed by routing of patients: D1, a PTI is scheduled within 14 days; D7-D14, genetic counselors perform a 20 min PTI in order to establish a pre-genetic counseling file, by collecting personal and family medical history via a structured questionnaire and; D10-17, routing: pre-genetic counseling appointment files are analyzed by a cancer geneticist with 3 possible conclusions: (a) priority face-to-face genetic counseling (FTFGC) appointment with a cancer geneticist, if the genetic test results have an immediate therapeutic impact; (b) non-priority FTFGC with a genetic counselor, or (c) no FTFGC required or substitution by a more appropriate index case. In the context of breast and/or ovarian cancer, 1012 patients received PTIs, 39.1% of which did not lead to FTFGC. The mean delay for non-priority FTFGC was maintained at 18 weeks and priority FTFGC appointments were guaranteed within 8 weeks. The required resources for 1012 patients was estimated at 0.12 FTE secretaries, 0.62 FTE genetic counselors and 0.08 FTE cancer geneticists and the procedure was shown to be cost-effective. This new procedure allows the suppression of up to 1/3 of appointments, guarantees priority for appointments with therapeutic impact and optimizes the interaction and breakdown of tasks between genetic counselors and cancer geneticists.Entities:
Keywords: Breast cancer; Genetic counseling; Genetic counselors; Ovarian cancer; Routing; Telephone interviews
Mesh:
Year: 2018 PMID: 29080081 DOI: 10.1007/s10689-017-0049-z
Source DB: PubMed Journal: Fam Cancer ISSN: 1389-9600 Impact factor: 2.375